WO2005060978A2 - Polymetaphosphate based formulations for therapy of microcrystalline arthropathies - Google Patents
Polymetaphosphate based formulations for therapy of microcrystalline arthropathies Download PDFInfo
- Publication number
- WO2005060978A2 WO2005060978A2 PCT/IT2004/000713 IT2004000713W WO2005060978A2 WO 2005060978 A2 WO2005060978 A2 WO 2005060978A2 IT 2004000713 W IT2004000713 W IT 2004000713W WO 2005060978 A2 WO2005060978 A2 WO 2005060978A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- crystals
- substance
- container
- dissolved
- Prior art date
Links
- 229940045916 polymetaphosphate Drugs 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title claims description 51
- 238000009472 formulation Methods 0.000 title description 34
- 208000036487 Arthropathies Diseases 0.000 title description 8
- 208000012659 Joint disease Diseases 0.000 title description 8
- 238000002560 therapeutic procedure Methods 0.000 title description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 239000003085 diluting agent Substances 0.000 claims abstract description 7
- 230000007170 pathology Effects 0.000 claims abstract description 5
- 239000013078 crystal Substances 0.000 claims description 62
- 239000000243 solution Substances 0.000 claims description 29
- 230000002225 anti-radical effect Effects 0.000 claims description 25
- 239000000126 substance Substances 0.000 claims description 24
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 18
- 229930195725 Mannitol Natural products 0.000 claims description 18
- 235000010355 mannitol Nutrition 0.000 claims description 18
- 239000000594 mannitol Substances 0.000 claims description 18
- 230000007928 solubilization Effects 0.000 claims description 18
- 238000005063 solubilization Methods 0.000 claims description 18
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 235000006708 antioxidants Nutrition 0.000 claims description 12
- 229960003080 taurine Drugs 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 8
- 229940005740 hexametaphosphate Drugs 0.000 claims description 7
- 239000002516 radical scavenger Substances 0.000 claims description 7
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 229960002849 glucosamine sulfate Drugs 0.000 claims description 6
- -1 hypochlorite anion Chemical class 0.000 claims description 6
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000000815 hypotonic solution Substances 0.000 claims description 3
- 125000005341 metaphosphate group Chemical group 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 235000021466 carotenoid Nutrition 0.000 claims description 2
- 150000001747 carotenoids Chemical class 0.000 claims description 2
- AZSFNUJOCKMOGB-UHFFFAOYSA-K cyclotriphosphate(3-) Chemical compound [O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 AZSFNUJOCKMOGB-UHFFFAOYSA-K 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- ZRMMVODKVLXCBB-UHFFFAOYSA-N 1-n-cyclohexyl-4-n-phenylbenzene-1,4-diamine Chemical compound C1CCCCC1NC(C=C1)=CC=C1NC1=CC=CC=C1 ZRMMVODKVLXCBB-UHFFFAOYSA-N 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 39
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 39
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 39
- 230000003381 solubilizing effect Effects 0.000 description 29
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 21
- 235000019983 sodium metaphosphate Nutrition 0.000 description 21
- 230000003064 anti-oxidating effect Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 208000002849 chondrocalcinosis Diseases 0.000 description 15
- 235000011180 diphosphates Nutrition 0.000 description 13
- 210000003622 mature neutrocyte Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 9
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 210000001612 chondrocyte Anatomy 0.000 description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 description 8
- 208000004434 Calcinosis Diseases 0.000 description 7
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 7
- 229920000388 Polyphosphate Polymers 0.000 description 7
- 229960004308 acetylcysteine Drugs 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000001205 polyphosphate Substances 0.000 description 7
- 235000011176 polyphosphates Nutrition 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000219061 Rheum Species 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000002308 calcification Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000003412 degenerative effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000007800 oxidant agent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 4
- 229940043256 calcium pyrophosphate Drugs 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 229960001338 colchicine Drugs 0.000 description 4
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 4
- OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010034464 Periarthritis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000009213 extracorporeal shockwave therapy Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000013081 microcrystal Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000037411 Aortic calcification Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 108010009413 Pyrophosphatases Proteins 0.000 description 2
- 102000009609 Pyrophosphatases Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229910052586 apatite Inorganic materials 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 108010027581 nucleoside triphosphate pyrophosphatase Proteins 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 206010006811 Bursitis Diseases 0.000 description 1
- 206010051714 Calciphylaxis Diseases 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 241000483002 Euproctis similis Species 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001460678 Napo <wasp> Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000006157 Rotator Cuff Tear Arthropathy Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000010588 calcific tendinitis Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000037329 crystal arthropathy Diseases 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 239000008235 industrial water Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940074371 monofluorophosphate Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 229910000487 osmium oxide Inorganic materials 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- JIWAALDUIFCBLV-UHFFFAOYSA-N oxoosmium Chemical compound [Os]=O JIWAALDUIFCBLV-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000000793 phophlogistic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Definitions
- the present invention relates to polymetaphosphate-based composition for therapy of microcrystalline arthropathies.
- Microcrystalline arthropathies are a group of inflammatory-degenerative pathologies, characterized by the deposition of mineral substances in articular and periarticular structures in crystalline form.
- ch ⁇ ndrocalcinosis is a disease characterized by microcrystalline deposits of calcium pyrophosphate dihydrate, Ca 2 [O(PO 3 ) 2 ](2H 2 O)
- this pathology manifests itself in association with other arthropathies of a pre- eminently degenerative nature such as osteoarthrosis, calcific periarthritis, tendinitis and calcific bursitis.
- calcific deposits are often not associated to specific clinical specifications, they can assume particular relevance in conditions such as calcific periarthritis of the shoulder, in which it is believed that such calcifications are partly responsible for the inflammatory degenerative manifestations of periarticular structure [Dieppe PA, Crocker P, Huskisson EC, Willoughby AD. Apatite deposition disease: a new arthropathy. Lancet 1: 266-268 (1976)].
- NTPPPH nucleoside triphosphate pyrophosphohydrolase
- pyrophosphates are an important source of inorganic phosphates, which have a fundamental role in bone mineralization. There is an equilibrium between pyrophosphates and phosphates: when the former prevail, they precipitate in crystalline form; when phosphates prevail, there a greater solubilization and reduction of pyrophosphate crystals [Anderson HC. Mechanisms of pathologic calcification. Rheum Dis Clin Am 14: 303-319 (1988); Rosen F, McCabe G, Quach J, Solan J, Terkeltaub R, Seegmiller JE, Lotz M. Differential effects of aging on human chondrocyte responses to transforming growth factor: increased pyrophosphate production and decreased cell proliferation. Arthritis Rheum
- CPPD crystals have elongated rhomboidal shape, although at times they are highlighted in the shape of long or short rods and small squares, whereas HAP crystals are smaller and have needle or rod shape.
- acute pseudogout attacks are due to the release into the articular cavity (synovial liquid) of CPPD crystals, which are coated (opsonized) with proteins (especially IgG) and then recognized and phagocytosed by polymorphonuclear neutrophils (PMN).
- ROS reactive oxygen species
- the most widely used treatment for the acute form consists of performing an arthrocentesis on the inflamed articulation, possibly associated to articular washing with physiological solution and/or local infiltration of corticosteroids [Fitzgerald RH Jr.
- polymetaphosphates are particularly effective in the treatment of calcareous deposits such as tartar, they are important ingredients in anti-plaque tooth pastes [Draus F.M. et al. Pyrophosphate and hexametaphosphate effects in vitro calculus formation. Archs. Oral Biol. 15: 893-896 (1970); McClanahan S.F., White D.J., Cox E.R. Dentifrice compositions containing polyphosphate and monofluorophosphate. US Patent 6,190,644 (2002)].
- the object of the invention is to provide a soluble pharmaceutical solution comprising an effective amount of at least one linear or cyclic polymetaphosphate or a soluble and pharmaceutically acceptable salt thereof, and appropriate diluents.
- the salt of the polymetaphosphate is a sodic salt (NaPO 3 ) n ; more preferably, it is included in the following group: polymeric metaphosphate (SMP, formula a); tripolymetaphosphate (PSTP, formula b); cyclic trimetaphosphate (TSMP, formula c), cyclic hexametaphosphate (SEMP, formula d).
- the composition further comprises effective quantities of anti-oxidizers and/or ROS scavengers, such as mannitol, vitamin E, vitamin C, carotenoids, tocopherol, taurine, glucosamine sulfate, glucosamine hydrochloride.
- anti-oxidizers and/or ROS scavengers such as mannitol, vitamin E, vitamin C, carotenoids, tocopherol, taurine, glucosamine sulfate, glucosamine hydrochloride.
- N-acetylcysteine glutatione.
- due to their effectiveness, tolerability and simplicity of preparation are to be preferred mannitol, taurine and/or glucosamine or salts thereof are to be preferred.
- Mannitol is a power scavenger of oxydryl radicals [Chaturvedi V, Wong B, Newman SL. Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. J Immunol 156: 3836-3840 (1996)].
- Taurine is a power scavenger of the hypochlorite anion, of nitroxide radicals and of all ROS produced by PMN and/or activated macrophages [Park E, Alberti J, Quinn MR, Schuller-Levis G.
- IL-6 and IL-8 Taurine chloramine inhibits the production of superoxide anion, IL-6 and IL-8 in activated human polymorphonuclear leukocytes. Adv Exp Med Biol 442: 177-182 (1998)].
- Polymetaphosphate by itself is not able to solubilize the calcium-based crystals (Ca pyrophosphates, hydroxyapatite) responsible for some arthropathies, but it is an anti-oxidizing agent that acts in synergy with known anti-oxidizers, with consequent reduction of inflammatory phenomena.
- the formulation of the invention is also associated to one or more scavenger substances.
- the obtained solutions can be injected directly into the articulations, or they can be used for continuously washing said articulations, with variable concentrations both of the polymetaphosphates and of the anti-oxidizing agents, in order to favor the solubilization of the microcrystals responsible for articulation calcification, or the reduction of inflammatory "noxa".
- These solutions must be isotonic, in consideration of their intra- articular use (isotony between 270 and 328 mOsmol/liter). However, it is also possible to hypothesize the use of hypo/hypertonic solutions to be used in the various therapeutic stages.
- the formulation of the invention allows to inhibit the presence of ROS at the level of the articular structures produced by the phagocytosis performed by the PMN and/or macrophages at the crystalline structure level. This mechanism is responsible for oxidation stress, which is an important component of the inflammatory process, the latter being the basis for pseudogout attacks.
- the formulations in particular those containing sodium hexametaphosphate, alone or in association with anti-radicals and/or anti-oxidizers, were tested in vitro to assess the ability to solubilize synthetic CPPD crystals (both monocline and tricline).
- solubilization tests on the aforesaid crystals were also conducted ex vivo on calcified meniscii removed by arthroscopic meniscectomy from patients affected by chondrocalcinosis. Moreover, cytotoxicity tests were conducted on the solutions used on cultures of human chondrocytes.
- Another object of the invention is to provide a pharmaceutical formulation, injectable in intra-articular fashion, comprising a first container, containing the composition according to one of the claims 1 through 3 in powder form, and a second container, containing a solution of diluent in which is dissolved at least one substance with anti- radical action and/or one substance with anti-oxidizing action; the composition of the first container is dissolved before use.
- the volume of the formulation varies from 5 to
- the diluent solution can be used in association with polymetaphosphates or not, in order to exploit their anti-radical and anti-oxidizing action.
- the formulation of the invention can also be used for the continuous washing of an articulation.
- the volume of the formulation varies from 5 to 50 ml.
- a pharmaceutical containment formulation to be used after the solubilization of CPPD or HAP crystals in an articulation comprising a container containing a slightly hypotonic solution of dilutant, injectable in intra-articular fashion, in which is dissolved at least one substance with anti-radical and/or anti- oxidizing action.
- Containment formulations have a volume that may vary from 5 to 50 ml.
- Example 1 PREPARATION OF SOLUBILIZING SOLUTIONS IN PBS BUFFER solutions containing polymetaphosphates, both linear and cyclic, were prepared, and pH and osmolality were measured, as shown in the following Table 1.A. Table l.A - Preparation of solubilizing solutions with polymetaphosphates in PBS
- Example 2 MEASUREMENT OF SOLUBILIZING ACTIVITY ON CPPD CRYSTALS
- 5 mg of synthetic CPPD crystals both tricline and monocline (with average size 1-30 ⁇ m) were added to 5 ml of phosphate buffer without Ca 2+ and Mg 2+ (PBS) containing different types of polymetaphosphate at the concentration of 5 mg/ml (the four solutions mentioned in Table 1.A).
- the suspension was maintained at 37°C for 1 hour under continuous agitation and subsequently filtered through 0.22 ⁇ m filters.
- solubilizing power of the examined polymetaphosphates on CPPD microcrystals can be expressed in the following order: SEMP > SMP > PSTP > TSMP.
- SEMP sodium hexametaphosphate has the greatest solubilizing activity on calcium pyrophosphate, whereas cyclic sodium trimetaphosphate has practically no solubilizing capacity.
- SEMP sodium hexametaphosphate
- Table 2.B Profile of the dissolving capacity of SEMP (5mg/ml) on CPPD crystals after progressively greater time intervals.
- Example 3 SOLUBILIZING EFFECT ON HAP CRYSTALS Description of the solubilization procedure and analysis method With a method similar to the preceding example (using 8 mg of HAP crystals), the dissolving capacities of the formulations described in Table 1.A were also studied on synthetic microcrystals of HAP (10-20 ⁇ m). Solubilization results and conclusions The results obtained can be summarized in the following Table 3. A Table 3. A - Solubilizing effect on HAP crystals after 1 hour of incubation at 37°C in PBS
- Example 4 CHECK OF CYTOTOXIC EFFECT ON CHONDROCYTES Description of the cytotoxicity test Samples of articular cartilage were obtained from the femoral heads of osteoarthritis patients subjected to hip prosthetization. Immediately after removal, portions of healthy cartilage were removed aseptically and 2 mm fragments were washed in physiological solution with antibiotics, then digested with 1 mg/ml of clostridial collagenase in PBS with antibiotics for 14-18 hours at 37°C with moderate agitation. The solution was then filtered, washed in physiological solution and centrifuged.
- chondrocytes were found to be vital with the method of the Trypan blue vital dye, then pre-washed and left in plates with suitable culture medium at 37°C and 5% of CO 2 .
- the cells thus obtained were incubated with progressively greater concentrations of polymetaphosphates in PBS (pH 7.4) for 24 hours (6 wells for each tested concentration).
- the control culture was obtained incubating cells with PBS alone for 24 hours. Cytotoxicity was determined after 1 day of exposure both with polymeric sodium metaphosphate (SMP) and with cyclic sodium hexametaphosphate (SEMP) with the tetrazole salt (MTT) method.
- SMP polymeric sodium metaphosphate
- SEMP cyclic sodium hexametaphosphate
- MTT tetrazole salt
- the pharmaceutical formulations L and N containing SEMP respectively with mannitol + taurine + N-acetylcysteine and with mannitol + N-acetylcysteine, were found to be inactive in the solubilization of CPPD crystals, as the dissolving medium almost completely loses its potential with respect to CPPD crystals and the concentration of calcium in the filtrate is below the limit of receivability of the technique employed.
- the aforesaid formulations Ol, FI, LI, NI, containing SMP with different compounds having anti-radical and/or anti-oxidizing activity were evaluating for their solubilizing capacity on CPPD crystals.
- the pharmaceutical formulations L and N containing SEMP respectively with mannitol + taurine + N-acetylcysteine and with mannitol + N-acetylcysteine, were found to be inactive in the solubilization of HAP crystals, as the dissolving medium almost completely loses its potential with respect to HAP crystals and the concentration of calcium in the filtrate is below the limit of receivability of the technique employed.
- the aforesaid formulations Ol, FI, LI, NI, containing SMP with different compounds having anti-radical and/or anti-oxidizing activity were evaluating for their solubilizing capacity on HA crystals.
- the PMNs were obtained from samples of peripheral venous blood of healthy subjects by centrifuging in density gradient :polymorphoprep (Nycomed), which, once centrifuged, forms a density gradient whereon the blood cells are separated. The purity (>90%) and the vitality (>95%) of the cell population were tested by examining a strip and conducting the trypan blue exclusion test. Thereafter, to a portion (100 ⁇ l) of a suspension containing 10 6 PMN ml " ' of PBS, were added 100 ⁇ l of luminol (2 mg in 10 ml of NaOH 0.01M subsequently diluted 1:10 with PBS) and 10 ⁇ l of stimulator.
- Formulations containing SMP have also shown a powerful inhibitory effect on the chemiluminescence produced by human PMNs with the procedure described above, with results which may be superposed with those already observed with hexametaphosphate.
- Example 7 EFFECT ON THE VITALITY OF HUMAN
- PMN POLYMORPHONUCLEATES
- the solutions were prepared solubilizing the sodium hexametaphosphate in PBS and adding PMNs (lxl0 5 /ml), obtained from venous blood of healthy volunteers. Incubation was performed at 37°C for 5 minutes. Subsequently, Trypan was added and the cells were observed with the microscope, calculating the number of vital cells. Tests with SEMP
- the preparation was incubated for 25 minutes at 37°C; subsequently, 50 ⁇ l of superoxide dismutase (SOD) 1 mg/ml, 75000 units (Sigma) to stop the reaction, lastly centrifuging for 10 minutes at 4°C and a spectrophotometric reading (Beckman DU6) of the surnatant at 550 and 468 nm.
- SOD superoxide dismutase
- the "white” was prepared introducing the SOD in a sample before all other reactants.
- the PMNs were prepared as described previously, the stimulator (PMA) was prepared as described in English's method. The results are expressed in nMoles/10 6 PMNs.
- the formulations C, E and G can also be considered the formulations for the containment or rather the washing of the articulation after intervening with solutions containing sodium hexametaphosphate. It can be considered as a point reached for containment solutions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04806878A EP1696939A2 (en) | 2003-12-22 | 2004-12-21 | Polymetaphosphate based formulations for therapy of microcrystalline arthropathies |
CA002550300A CA2550300A1 (en) | 2003-12-22 | 2004-12-21 | Polymetaphosphate based formulations for therapy of microcrystalline arthropathies |
US10/583,605 US20100173010A1 (en) | 2003-12-22 | 2004-12-21 | Polymetaphosphate based formulations for therapy of microcrystalline arthropathies |
JP2006546486A JP2007534655A (en) | 2003-12-22 | 2004-12-21 | Polymetaphosphate-based formulations for the treatment of microcrystalline arthropathy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2003A000590 | 2003-12-22 | ||
IT000590A ITRM20030590A1 (en) | 2003-12-22 | 2003-12-22 | POLYMETPHOSPHATE-BASED FORMULATION FOR THE CARE OF MICROCRYSTALLINE ARTHROPATHIES. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005060978A2 true WO2005060978A2 (en) | 2005-07-07 |
WO2005060978A3 WO2005060978A3 (en) | 2005-08-04 |
Family
ID=34708532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2004/000713 WO2005060978A2 (en) | 2003-12-22 | 2004-12-21 | Polymetaphosphate based formulations for therapy of microcrystalline arthropathies |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100173010A1 (en) |
EP (1) | EP1696939A2 (en) |
JP (1) | JP2007534655A (en) |
CA (1) | CA2550300A1 (en) |
IT (1) | ITRM20030590A1 (en) |
WO (1) | WO2005060978A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUB20160717A1 (en) * | 2016-02-12 | 2017-08-12 | Over S R L | Intra-articular application of polymetaphosphates for the therapy of microcrystal deposition arthropathies. |
WO2018165132A1 (en) * | 2017-03-06 | 2018-09-13 | University Of Houston System | Polyphosphates as inhibitors of calcium crystallization |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2846873B1 (en) * | 2012-05-10 | 2017-07-12 | Institut National de la Santé et de la Recherche Medicale | Sodium thiosulfate for the treatment of ectopic calcifications |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1077682A (en) * | 1952-06-09 | 1954-11-10 | Monsanto Chemicals | Improvements in Antioxidants and the Chemical Compositions Containing Them |
GB817181A (en) * | 1956-10-24 | 1959-07-29 | Bristol Lab Inc | Therapeutic products containing tetracycline |
GB1132233A (en) * | 1965-10-22 | 1968-10-30 | Harvey Ashmead | Medicinal compositions containing sequestering and chelating agents |
US3541208A (en) * | 1968-09-10 | 1970-11-17 | Arcom Holding Corp | Relief of arthritis with a soluble silicate and a soluble polyphosphate |
WO2000066599A1 (en) * | 1999-04-30 | 2000-11-09 | Oberthuer Walter | Antioxidative vitamin b6 analogs |
US20020022052A1 (en) * | 2000-04-06 | 2002-02-21 | Dransfield Charles William | Transdermal delivery system |
US6399093B1 (en) * | 1999-05-19 | 2002-06-04 | Advanced Medical Instruments | Method and composition to treat musculoskeletal disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030157187A1 (en) * | 1996-12-02 | 2003-08-21 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
ATE293451T1 (en) * | 1996-12-13 | 2005-05-15 | Lescarden Inc | TREATMENT OF OSTEOARTHRITIS BY ADMINISTRATION OF POLY-N-ACETYL-D-GLUCOSAMINE |
JP2003089647A (en) * | 1999-03-10 | 2003-03-28 | Takada Seiyaku Kk | Articular disease therapeutic agent |
-
2003
- 2003-12-22 IT IT000590A patent/ITRM20030590A1/en unknown
-
2004
- 2004-12-21 WO PCT/IT2004/000713 patent/WO2005060978A2/en active Application Filing
- 2004-12-21 CA CA002550300A patent/CA2550300A1/en not_active Abandoned
- 2004-12-21 JP JP2006546486A patent/JP2007534655A/en active Pending
- 2004-12-21 US US10/583,605 patent/US20100173010A1/en not_active Abandoned
- 2004-12-21 EP EP04806878A patent/EP1696939A2/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1077682A (en) * | 1952-06-09 | 1954-11-10 | Monsanto Chemicals | Improvements in Antioxidants and the Chemical Compositions Containing Them |
GB817181A (en) * | 1956-10-24 | 1959-07-29 | Bristol Lab Inc | Therapeutic products containing tetracycline |
GB1132233A (en) * | 1965-10-22 | 1968-10-30 | Harvey Ashmead | Medicinal compositions containing sequestering and chelating agents |
US3541208A (en) * | 1968-09-10 | 1970-11-17 | Arcom Holding Corp | Relief of arthritis with a soluble silicate and a soluble polyphosphate |
WO2000066599A1 (en) * | 1999-04-30 | 2000-11-09 | Oberthuer Walter | Antioxidative vitamin b6 analogs |
US6399093B1 (en) * | 1999-05-19 | 2002-06-04 | Advanced Medical Instruments | Method and composition to treat musculoskeletal disorders |
US20020022052A1 (en) * | 2000-04-06 | 2002-02-21 | Dransfield Charles William | Transdermal delivery system |
Non-Patent Citations (2)
Title |
---|
CINI R ET AL: "Dissolution of calcium pyrophosphate crystals by polyphosphates: An in vitro and ex vivo study" ANNALS OF THE RHEUMATIC DISEASES, vol. 60, no. 10, October 2001 (2001-10), pages 962-967, XP002328845 ISSN: 0003-4967 * |
RYAN L M ET AL: "Stimulation of cartilage inorganic pyrophosphate elaboration by ascorbate" MATRIX 1991 GERMANY, vol. 11, no. 4, 1991, pages 276-281, XP009047873 ISSN: 0934-8832 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUB20160717A1 (en) * | 2016-02-12 | 2017-08-12 | Over S R L | Intra-articular application of polymetaphosphates for the therapy of microcrystal deposition arthropathies. |
WO2017138031A1 (en) * | 2016-02-12 | 2017-08-17 | Over S.R.L. | Intra-articular administration of polymetaphopsphates for the treatment of crystal arthropaties |
CN108883128A (en) * | 2016-02-12 | 2018-11-23 | 欧弗有限公司 | Intra-articular application polymetaphosphate is to treat crystallographic arthropathy |
WO2018165132A1 (en) * | 2017-03-06 | 2018-09-13 | University Of Houston System | Polyphosphates as inhibitors of calcium crystallization |
Also Published As
Publication number | Publication date |
---|---|
CA2550300A1 (en) | 2005-07-07 |
ITRM20030590A1 (en) | 2005-06-23 |
EP1696939A2 (en) | 2006-09-06 |
US20100173010A1 (en) | 2010-07-08 |
JP2007534655A (en) | 2007-11-29 |
WO2005060978A3 (en) | 2005-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016011978A1 (en) | Composition with multiple oral treatment and healthcare functions and preparation method therefor | |
Tu et al. | Berberine's effect on periodontal tissue degradation by matrix metalloproteinases: an in vitro and in vivo experiment | |
US20090170808A1 (en) | Oral agent for improving and protecting the function of joint comprising hyaluronic acid-phospholipid complexes | |
ES2344677T3 (en) | MEDICATIONS FOR ARTICULAR DISEASES. | |
EP2194977A1 (en) | Method of preventing nephrocalcinosis | |
Ohata et al. | The effect of diphosphonate on calcium phosphate crystallization in urine in vitro | |
Saw et al. | Effects of inositol hexaphosphate (phytate) on calcium binding, calcium oxalate crystallization and in vitro stone growth | |
KR102285724B1 (en) | Composition for regenerating cartilage comprising polydeoxyribonucleotide and hyaluronic acid | |
US20100173010A1 (en) | Polymetaphosphate based formulations for therapy of microcrystalline arthropathies | |
RU2712168C1 (en) | Osteoarthritis treatment composition comprising hydrophilised sulphasalasine and hyaluronic acid, and a method of producing said composition | |
JP2013503841A (en) | Use of indigestible oligosaccharides | |
JPS5931789A (en) | Gel-like calcium salt of 1-hydroxy-3-aminopropane- 1,1-diphosphoric acid | |
JP5051768B2 (en) | Pharmaceutical composition for treatment / prevention of musculoskeletal diseases | |
US20110081410A1 (en) | Therapeutic agent for local inflammation | |
JP2000256196A (en) | Anti-inflammatory and anti-allergic medicine | |
EP3413901B1 (en) | Intra-articular administration of polymetaphopsphates for the treatment of crystal arthropaties | |
Osunde et al. | Role of warm saline mouth rinse in prevention of alveolar osteitis: a randomized controlled trial | |
JP2003160491A (en) | Diuridine phosphate-containing eye drop | |
CH676324A5 (en) | Haemostatic dentifrice compsns. - contain phospholipid and amphoteric surfactant | |
US20220168223A1 (en) | Liposomes encapsulating adenosine | |
US20220193032A1 (en) | Pharmaceutical compositions comprising statins and hyaluronic acid derivatives | |
JP6853547B2 (en) | Composition for inhibiting collagen degradation | |
Kumar et al. | Formulation And Evaluation Of Doxycycline Proniosomal Gel For The Treatment Of Periodontitis | |
Maimansomsuk et al. | The synthesis of Tween80/calcium phosphate nanocomposite bioactive gelatine-based gels as a proof of concept for tooth sensitivity home-treatment | |
Krämer et al. | Iodine release and antibacterial effects of a wound paste combined with PVP-iodine powder and/or solution in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2550300 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006546486 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004806878 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004806878 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10583605 Country of ref document: US |